Article
Feasibility and clinical impact of routine molecular testing of gastrointestinal cancers at a tertiary centre with a multi-gene, tumor-agnostic, next generation sequencing panel.
Acta oncologica (Stockholm, Sweden) - 1 Dec 2020
Bregni Giacomo, Sticca Tiberio, Camera Silvia, Akin Telli Tugba, Craciun Ligia, Trevisi Elena, Pretta Andrea, Kehagias Pashalina, Leduc Sophia, Senti Chiara, Deleporte Amélie, Vandeputte Caroline, Saad Everardo Delforge, Kerger Joseph, Gil Thierry, Piccart-Gebhart Martine, Awada Ahmad, Demetter Pieter, Larsimont Denis, Hendlisz Alain, Aftimos Philippe, Sclafani Francesco
Abstract excerpt
BACKGROUND: High-throughput sequencing technologies are increasingly used in research but limited data are available on the feasibility and value of these when routinely adopted in clinical practice. MATERIAL AND METHODS: We analyzed all consecutive cancer patients for whom genomic testing by a 48-gene next-generation sequencing (NGS) panel (Truseq Amplicon Cancer Panel, Illumina) was requested as part of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.